FIA
BBOT

FNY Investment Advisers’s BridgeBio Oncology BBOT Stock Holding History

FNY Investment Advisers’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$1K – 1562
2025
Q3 		$1K Sell
100
-27,084
-100% -$282K ﹤0.01% 1200
2025
Q2 		$289K Buy
+27,184
New +$294K 0.12% 168

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

FNY Investment Advisers's BBOT Position: Q4 2025 in Review

FNY Investment Advisers sold out of BridgeBio Oncology (BBOT) in Q4 2025, closing a stake of 100 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in BBOT in Q2 2025 and held it in 2 quarters. The position peaked at $289K in Q2 2025. 53 funds tracked by Wall St. Rank hold BBOT as of Q4 2025.

  • FNY Investment Advisers reported no remaining BridgeBio Oncology position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 100 BridgeBio Oncology shares in Q4 2025, an estimated $1K.
  • FNY Investment Advisers first reported a position in BridgeBio Oncology in Q2 2025 and held it in 2 quarters.
  • FNY Investment Advisers's BridgeBio Oncology position peaked at $289K in Q2 2025.
  • 53 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.